{"id":819314,"date":"2025-02-27T10:46:04","date_gmt":"2025-02-27T15:46:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/market-news-alert-nuvectis-pharma-receives-18-price-target-and-buy-rating-from-lucid-capital-markets\/"},"modified":"2025-02-27T10:46:04","modified_gmt":"2025-02-27T15:46:04","slug":"market-news-alert-nuvectis-pharma-receives-18-price-target-and-buy-rating-from-lucid-capital-markets","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/market-news-alert-nuvectis-pharma-receives-18-price-target-and-buy-rating-from-lucid-capital-markets\/","title":{"rendered":"Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets"},"content":{"rendered":"

<\/p>\n

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets<\/b><\/p>\n

Precision oncology player Nuvectis Pharma receives a buy recommendation and price target with a significant premium from Lucid Capital Markets. Report highlights Nuvectis\u2019 potential to generate hundreds of millions of dollars in revenue and notes upcoming phase 1a clinical data as a potential catalyst<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nMarket News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (Nasdaq: NVCT) with a Buy rating and a price target of $18. The firm’s report highlights Nuvectis’ promising oncology pipeline, particularly its lead asset, NXP900, a SRC\/YES1 inhibitor targeting squamous cell carcinomas with high unmet need.<\/p>\n

\nLucid’s report emphasizes the strong potential of NXP900, which is currently in Phase 1 clinical trials and has shown an encouraging safety profile while continuing dose escalation. The firm projects peak non-risk-adjusted sales of over $900 million for NXP900 across multiple cancer indications by 2041.<\/p>\n

\nAdditionally, Nuvectis\u2019 second asset, NXP800, a GCN2 activator, is in Phase 1b trials targeting ARID1a-mutated ovarian cancer. Although previous dosing regimens required adjustments due to safety concerns, the report views NXP800 as a potential upside with limited downside risk. The company\u2019s financial position is another key factor supporting the Buy rating. With cash and equivalents of $18.5 million as of year-end 2024 and a recent $15.5 million public offering in Q1 2025, Lucid forecasts that Nuvectis has a cash for a significant period of time, allowing it to continue advancing its clinical programs.<\/p>\n

\nLucid firm sees upcoming Phase 1a data in 2025 as a potential catalyst for the stock, along with the planned initiation of a Phase 1b trial and combination studies later this year.<\/p>\n

Market News Alerts is not responsible for the price target nor does it endorse it. Readers are advised to refer to the full report on various systems and the disclaimers\/disclosures it may be subject to.<\/i><\/p>\n

Recent News from Nuvectis<\/b><\/p>\n